Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in MDD Comorbid With SAD
NCT02294305Phase 4Unknown
- Sponsor
- Medical Research Network
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and Social Anxiety Disorder (SAD) comparing Vortioxetine with Placebo (2 arms). Primary endpoint: Clinical Global Impression of Improvement Responder Rate at 12 weeks. Status: unknown.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT02294305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294305.